CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug ConjugateDanielle C. Kirkey, Melia Blankenfeld,Tiffany Hylkema,Deryk Loo,Ashley Ward,Leila Robinson, Jack H. Peplinski, Logan K. Wallace,Laura Pardo,Andrew J. Menssen,Rhonda E. Ries,Soheil MeshinchiBLOOD（2023）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
